医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Synaptive Medical Receives CE Mark in Europe and Regulatory Approval in Australia for BrightMatter™ Plan

2017年04月25日 AM12:50
このエントリーをはてなブックマークに追加


 

TORONTO

Synaptive Medical Inc., a medical device and technology company, has received its first CE Mark as well as regulatory approval in Australia. The approval opens European and Australian markets to BrightMatter™ Plan, a state-of-the-art neurosurgical planning system that automatically generates dynamic tractography, enabling surgeons to easily create preoperative plans that allow for less disruptive, more accurate surgery.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170424006099/en/

BrightMatter™ Plan by Synaptive Medical automatically generates 3D, dynamic whole brain tractography ...

BrightMatter™ Plan by Synaptive Medical automatically generates 3D, dynamic whole brain tractography using an advanced type of MRI called diffusion tensor imaging to provide a complete picture, representing the white matter in the brain. The software makes this unprecedented automation and level of detail clinically available for the first time. (Photo: Business Wire)

“Europe and Australia are home to many highly influential clinician-researchers in neurosurgery. We look forward to opportunities to collaborate and understand their pre-operative planning needs,” said Cameron Piron, Synaptive’s President and co-founder. “We anticipate that Plan will be the first of many Synaptive products to receive regulatory approval to support better outcomes for patients in Europe and Australia.”

BrightMatter Plan is a part of Synaptive’s innovative solution that includes advanced imaging, informatics, surgical planning, navigation and robotic visualization with a digital microscope for brain surgery. BrightMatter Plan by Synaptive Medical automatically generates 3D, dynamic whole brain tractography using an advanced type of MRI called diffusion tensor imaging to provide a complete picture, representing the white matter in the brain. The software makes this unprecedented automation and level of detail clinically available for the first time. With this information, BrightMatter Plan allows surgeons to easily explore multiple approaches to determine the least invasive access point and safest route to the surgical target.

This enhanced pre-surgical visualization may contribute to reduced complications, and may enable access to previously inaccessible brain locations. The resulting tractography and surgical plan can then be exported to navigation systems, such as BrightMatter Guide, for use in the operating room.

“This is a key year for our international expansion as Synaptive scales up in global healthcare markets,” said Piron. “Expanding our presence in the UK, Ireland, Germany, Switzerland, the Nordic countries, Singapore, and Australia is another step toward bringing Canadian innovation to the world.”

BrightMatter Plan is FDA, CE Mark, Health Canada and TGA approved.

About Synaptive Medical
Synaptive Medical Inc., a Toronto-based medical device and technology company, collaborates with leading clinicians and healthcare systems to cross traditional barriers and enable continuous improvement in care delivery, in and beyond the operating room. Their integrated BrightMatter™ solutions, which include surgical planning, navigation and visualization, robotics and an integrated informatics platform, are designed and manufactured to give clinicians the information they need to ensure the best possible outcomes for patients.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170424006099/en/

CONTACT

Media Contact
Synaptive Medical, Inc.
Elizabeth
Monier-Williams, 647-925-3435 x169
Director, Marketing
Communications

同じカテゴリーの記事 

  • Dr. Reddy’s Laboratories launches Versavo® (bevacizumab) in the UK
  • アクティビストキャンペーンサイトStrengthen Wakamoto(TOKYO:4512)の公開:株式会社ナナホシマネジメント
  • Nanahoshi Management Ltd.: Strengthen Wakamoto Activist Campaign (TOKYO:4512) Is Released
  • 冠科生物连续三年荣膺T+ Employer® 卓越雇主
  • Crown Bioscienceが3年連続でT+ Employer®に認定される